{"id":61387,"date":"2026-03-26T14:54:45","date_gmt":"2026-03-26T06:54:45","guid":{"rendered":"https:\/\/flcube.com\/?p=61387"},"modified":"2026-03-26T14:54:46","modified_gmt":"2026-03-26T06:54:46","slug":"xtalpi-achieves-first-profitability-ai-drug-discovery-revenue-surges-418-to-rmb-538m-global-sales-hit-rmb-803m","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=61387","title":{"rendered":"XtalPi Achieves First Profitability \u2013 AI Drug Discovery Revenue Surges 418% to RMB 538M, Global Sales Hit RMB 803M"},"content":{"rendered":"\n

QuantumPharm Inc.<\/strong> (HKG: 2228<\/a>), operating as XtalPi Inc.<\/strong>, reported 2025 financial results<\/strong>, achieving first annual profitability<\/strong> with net profit of RMB 135 million (USD 19.6 million)<\/strong>. The company became the first profitable Hong Kong-listed company in the AI for Science (AI4S) sector<\/strong>, with global sales skyrocketing 201.2% YoY to RMB 803 million (USD 116 million)<\/strong>. The drug discovery solutions business<\/strong> drove exceptional growth, surging 418.9% to RMB 538 million<\/strong> fueled by antibody business expansion<\/strong> and milestone achievements<\/strong> across partner pipelines.<\/p>\n\n\n\n

Financial Highlights<\/h2>\n\n\n\n
Metric<\/th>2025 Result<\/th>YoY Change<\/th>Sector Significance<\/th><\/tr><\/thead>
Global Sales<\/strong><\/td>RMB 803 million (USD 116M)<\/td>+201.2%<\/strong><\/td>Hypergrowth validates AI drug discovery commercial model<\/td><\/tr>
Net Profit<\/strong><\/td>RMB 135 million (USD 19.6M)<\/td>First profitable year<\/strong><\/td>First HK-listed AI4S profitability<\/strong> \u2013 sector milestone<\/td><\/tr>
Drug Discovery Solutions<\/strong><\/td>RMB 538 million (USD 78M)<\/td>+418.9%<\/strong><\/td>Core engine of growth; antibody business + partner milestones<\/td><\/tr>
AI Models Deployed<\/strong><\/td>200+ industry models<\/strong><\/td>Cumulative<\/td>Full-chain coverage: target discovery \u2192 preclinical screening<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Business Segment Performance<\/h2>\n\n\n\n
Segment<\/th>2025 Revenue<\/th>Growth Driver<\/th>Strategic Impact<\/th><\/tr><\/thead>
Drug Discovery Solutions<\/strong><\/td>RMB 538M<\/td>Antibody business rapid expansion; partner\/incubated company milestone achievements<\/td>Profitability engine<\/strong> \u2013 high-margin SaaS + milestone economics<\/td><\/tr>
Materials Science (Battery, Semiconductor)<\/strong><\/td>RMB 265M (implied)<\/td>AI-driven R&D for energy and electronics sectors<\/td>Diversification beyond pharma; industrial AI applications<\/td><\/tr>
Total<\/strong><\/td>RMB 803M<\/td>AI platform scalability<\/strong> across verticals<\/td>Validation of AI for Science (AI4S)<\/strong> business model<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

AI Platform Progress<\/h2>\n\n\n\n
Capability<\/th>2025 Achievement<\/th>Competitive Position<\/th><\/tr><\/thead>
AI Model Portfolio<\/strong><\/td>200+ models<\/strong> covering entire drug discovery chain<\/strong><\/td>Most comprehensive AI platform in China biotech<\/td><\/tr>
Strategic Collaborations<\/strong><\/td>Systematic deepening with global pharma and biotech partners<\/strong><\/td>Revenue visibility through multi-year partnerships<\/td><\/tr>
Core Model Iteration<\/strong><\/td>Continuous algorithm improvement in molecular generation, ADMET prediction, protein structure<\/strong><\/td>Technical moat vs. emerging AI competitors<\/td><\/tr>
Novel Drug Platforms<\/strong><\/td>Expansion into antibody, ADC, PROTAC, siRNA<\/strong> modalities<\/td>Platform breadth supports diverse partner pipelines<\/strong><\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Strategic Context: AI4S Sector Leadership<\/h2>\n\n\n\n
Factor<\/th>Implication<\/th><\/tr><\/thead>
Profitability Milestone<\/strong><\/td>First HK-listed AI4S profitability<\/strong> validates unit economics<\/strong> of AI drug discovery; reduces skepticism about AI platform sustainability<\/td><\/tr>
Antibody Business Surge<\/strong><\/td>418% growth<\/strong> reflects biologics industry shift<\/strong> toward AI-enabled discovery; XtalPi captures trend with generative antibody design<\/strong><\/td><\/tr>
Partner Milestone Economics<\/strong><\/td>Revenue model shifts from pure SaaS fees<\/strong> to success-based milestones<\/strong> \u2013 aligns incentives and improves margins<\/td><\/tr>
Global Expansion<\/strong><\/td>“Global sales”<\/strong> designation suggests ex-China revenue contribution<\/strong> growing; positions for U.S.\/EU partnerships<\/strong><\/td><\/tr>
Sector Valuation<\/strong><\/td>Profitability supports premium valuation<\/strong> vs. pre-revenue AI biotech peers; potential index inclusion<\/strong> (Hang Seng Tech)<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n